The Value of Delaying Alzheimer’s Disease Onset : Forum for Health Economics and Policy

www.degruyter.com uses cookies, tags, and tracking settings to store information that help give you the very best browsing experience.
To understand more about cookies, tags, and tracking, see our Privacy Statement
I accept all cookies for the De Gruyter Online site

Jump to ContentJump to Main Navigation

Forum for Health Economics & Policy

Editor-in-Chief: Goldman, Dana

VolumeIssuePage

30,00 € / $42.00 / £23.00

Get Access to Full Text

The Value of Delaying Alzheimer’s Disease Onset

1 / Eileen Crimmins2 / Patricia St.Clair3

1Schaeffer Center for Health Policy and Economics, University of Southern California, 635 Downey Way, Los Angeles, CA 90089-3331, USA

2Davis School of Gerontology, University of Southern California, 3715 McClintock Ave., Los Angeles, CA, USA

3Schaeffer Center for Health Policy and Economics, University of Southern California, 635 Downey Way, Los Angeles, CA, USA

Corresponding author: Julie Zissimopoulos, PhD, Assistant Professor, Sol Price School of Public Policy and Associate Director, Schaeffer Center for Health Policy and Economics, University of Southern California, 635 Downey Way, Los Angeles, CA 90089-3331, USA, Phone: +213-821-7947, Fax: +213-740-3460, e-mail: .

Citation Information: Forum for Health Economics and Policy. Volume 18, Issue 1, Pages 25–39, ISSN (Online) 1558-9544, ISSN (Print) 2194-6191, DOI: 10.1515/fhep-2014-0013, November 2014

Publication History

Published Online:
2014-11-04

This article offers supplementary material which is provided at the end of the article.

Abstract

Alzheimer’s disease (AD) extracts a heavy societal toll. The value of medical advances that delay onset of AD could be significant. Using data from nationally representative samples from the Health and Retirement Study (1998–2008) and Aging Demographics and Memory Study (2001–2009), we estimate the prevalence and incidence of AD and the formal and informal health care costs associated with it. We use microsimulation to project future prevalence and costs of AD under different treatment scenarios. We find from 2010 to 2050, the number of individuals ages 70+ with AD increases 153%, from 3.6 to 9.1 million, and annual costs increase from $307 billion ($181B formal, $126B informal costs) to $1.5 trillion. 2010 annual per person costs were $71,303 and double by 2050. Medicare and Medicaid are paying 75% of formal costs. Medical advances that delay onset of AD for 5 years result in 41% lower prevalence and 40% lower cost of AD in 2050. For one cohort of older individuals, who would go on to acquire AD, a 5-year delay leads to 2.7 additional life years (about 5 AD-free), slightly higher formal care costs due to longer life but lower informal care costs for a total value of $511,208 per person. We find Medical advances delaying onset of AD generate significant economic and longevity benefits. The findings inform clinicians, policymakers, businesses and the public about the value of prevention, diagnosis, and treatment of AD.

Keywords: Alzheimer’s disease; Medicare; medical expenditures; medical innovation

Supplementary Article Materials

Comments (0)

Please log in or register to comment.